Options
Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study
Journal
Cancer
Journal Volume
130
Journal Issue
8
End Page
1291
Date Issued
2024-04-15
Author(s)
Piscaglia, Fabio
Ikeda, Kenji
Kudo, Masatoshi
Ikeda, Masafumi
Breder, Valery
Ryoo, Baek-Yeol
Mody, Kalgi
Ren, Min
Ramji, Zahra
Sung, Max W
Abstract
Lenvatinib is approved as a first-line treatment for patients with unresectable and/or recurrent hepatocellular carcinoma (HCC). Lenvatinib achieved promising clinical benefits in REFLECT but was associated with clinically significant treatment-emergent hypertension (CSTE-HTN, a grouped term), a common class effect of tyrosine kinase inhibitors. This post hoc analysis assessed the impact of CSTE-HTN on the efficacy and safety of lenvatinib in HCC.
Subjects
hepatocellular carcinoma; hypertension; lenvatinib; prognosis; statins; treatment outcome
Type
journal article